Although in lack of in vivo animal studies and clinical data, our work indicates that the Nrf2-TrxR axis is a potential target for reversing the drug resistance in CML. The gene discussed is NFE2L2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.